Neugenesis, PATH Sign Collaboration Agreement

Neugenesis has collaborated with PATH to develop an influenza vaccine production system. Under the agreement, Neugenesis would conduct proof of concept work to demonstrate the utility of the NeuBIOS protein production platform, for making seasonal and pandemic influenza vaccine.

The NeuBios platform would be used to make non-infectious, non-replicating virus-like particles (VLPs).

Kathleen Neuzil, Director of Influenza Vaccine Project at PATH, said: “PATH is delighted to be working with Neugenesis on this project in support of increasing the accessibility and affordability of influenza vaccines for people in low-income countries.”

Dorsey Stuart, CEO and Founder of Neugenesis, said: “Neugenesis is extremely pleased to be chosen by PATH, and we are excited to work with them toward the goal of bringing affordable medicines to underserved global communities. This begins a partnership with PATH that we hope to continue beyond influenza. Importantly, it provides us with an opportunity to demonstrate our platform for vaccine production.”